Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

InventisBio Co: Clinical Trials & FDA Approval Profile

InventisBio Co (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (7 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.9%
Median Closed Enrollment vs National (145 pts)141 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for InventisBio Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)9 (7)
Completed vs Stopped Early6 / 1 (5.9%)
Median Closed Actual Enrollment141 participants
Physical Hospital Site Disclosure43.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With InventisBio Co
Hospital Research SiteLocationShared Protocols
Shanghai Chest HospitalShanghai3
Peking University People's HospitalBeijing, Beijing Municipality2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by InventisBio Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05504083Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia PatientsPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the InventisBio Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI